Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8212176 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 33 Pages |
Abstract
Concurrent ipilimumab 10Â mg/kg with SRS is safe. The WBRT arm was closed early because of slow accrual but demonstrated safety with ipilimumab 3Â mg/kg. No patient experienced dose-limiting toxicity. Larger studies, including those with combination checkpoint inhibitor therapy and SRS, are warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Noelle L. MD, Evan J. MD, Hyun MD, Joshua D. MD, Shivank MD, Harriet MD, Constantine PhD, Kendra J. MD, Michael J. MD, Lyndon J. MD, Takami MD, PhD, Kari L. MD, Thomas DO, David A. MD, Christopher J. MD, James J. MD, Kevin D. MD, David W. MD, Wenyin MD,